ClinVar Miner

Submissions for variant NM_000023.4(SGCA):c.981C>T (p.Ser327=)

gnomAD frequency: 0.00013  dbSNP: rs368522117
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000413434 SCV000491801 uncertain significance not provided 2016-11-23 criteria provided, single submitter clinical testing The c.981 C>T variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. It was not observed with any significant frequency in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project. This nucleotide change results in a synonymous amino acid substitution at a position that it not conserved. Multiple in-silico splice prediction models predict c.981 C>T may reduce the strength of the natural splice donor site in intron 8 and lead to abnormal gene splicing. However, in the absence of RNA/functional studies, the actual effect of this sequence change is unknown.
Labcorp Genetics (formerly Invitae), Labcorp RCV001085556 SCV001120700 likely benign Autosomal recessive limb-girdle muscular dystrophy type 2D 2024-07-01 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV001085556 SCV001806716 uncertain significance Autosomal recessive limb-girdle muscular dystrophy type 2D 2021-07-22 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.